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Abstract: Cyclooxygenase 2 (COX-2) is a key enzyme of the tumorigenesis-inflammation interface and can
be induced by hypoxia. A pseudohypoxic transcriptional signature characterizes pheochromocytomas
and paragangliomas (PPGLs) of the cluster I, mainly represented by tumors with mutations in von
Hippel–Lindau (VHL), endothelial PAS domain-containing protein 1 (EPAS1), or succinate dehydrogenase
(SDH) subunit genes. The aim of this study was to investigate a possible association between underlying
tumor driver mutations and COX-2 in PPGLs. COX-2 gene expression and immunoreactivity were
examined in clinical specimens with documented mutations, as well as in spheroids and allografts derived
from mouse pheochromocytoma (MPC) cells. COX-2 in vivo imaging was performed in allograft mice.
We observed significantly higher COX-2 expression in cluster I, especially in VHL-mutant PPGLs, however,
no specific association between COX-2 mRNA levels and a hypoxia-related transcriptional signature
was found. COX-2 immunoreactivity was present in about 60% of clinical specimens as well as in MPC
spheroids and allografts. A selective COX-2 tracer specifically accumulated in MPC allografts. This study
demonstrates that, although pseudohypoxia is not the major determinant for high COX-2 levels in PPGLs,
COX-2 is a relevant molecular target. This potentially allows for employing selective COX-2 inhibitors
as targeted chemotherapeutic agents and radiosensitizers. Moreover, available models are suitable for
preclinical testing of these treatments.
Keywords: VHL; NF1; EPAS1; hypoxia-inducible factor; inflammation; radiosensitization; succinate
dehydrogenase; mouse pheochromocytoma cells; immunohistochemistry; fluorescence imaging
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1. Introduction
Over the past few decades, advances in genetic testing have substantially facilitated the
identification of germline and somatic mutations in tumor susceptibility genes in about 60% of
adrenal pheochromocytomas and their extra adrenal counterparts, paragangliomas (summarized as
PPGLs) [1–4]. Gain-of-function mutations in proto-oncogenes such as rearranged during transfection
(RET; germline or somatic), endothelial per-arnt-sim domain-containing protein 1 (EPAS1; somatic),
and Harvey rat sarcoma viral oncogene homolog (HRAS; somatic); and loss-of-function mutations in
tumor suppressor genes such as von Hippel–Lindau (VHL; germline or somatic), neurofibromin 1 (NF1;
germline or somatic), transmembrane protein 127 (TMEM127; germline), and myc-associated factor X
(MAX, germline or somatic), as well as mutations in all four succinate dehydrogenase subunits (SDHD,
SDHC, SDHB, and SDHA; germline) and SDH assembly factor 2 (SDHAF2; germline) have been
implicated in the tumorigenesis of PPGLs [2,5–11]. Beyond that, the number of PPGL susceptibility
gene candidates is still increasing, e.g. [4,12–21], although most of them seem to play a minor role in
PPGL according to the low proportion of patients related to these genes described so far.
Gene expression profiling provided the basis for classifying PPGLs according to their main
transcriptional signatures underlying the aforementioned mutations: cluster I presents with activation
of pseudohypoxic signaling pathways and includes mainly VHL-, EPAS1-, and SDHx-mutant cases;
cluster II is enriched in kinase receptor signaling pathways and is comprised of RET-, NF1-, TMEM127-,
MAX-, and HRAS-mutant cases [22,23]. Both pseudohypoxia and kinase receptor signaling are
involved in regulating apoptosis, proliferation, invasion, and metastasis, and angiogenesis via different
mechanisms, but can also contribute to inflammatory conditions in various tumor entities [24–27].
Cyclooxygenases (COX) 1 and 2, also referred to as prostaglandin-endoperoxide synthases (PTGS
1 and 2; EC 1.14.99.1), catalyze the conversion of arachidonic acid to prostaglandin H2 (PGH2). PGH2
is then converted into a variety of other prostanoids, determined by certain downstream synthase and
isomerase pathways. Prostanoids comprise other prostaglandins such as PGE2 and PGF2α, prostacyclin
(PGI2) and thromboxanes (e.g., TXA2). These compounds are ligands for G protein-coupled receptors
and act as potent para- and endocrine mediators of metabolic processes in homeostasis, but also
in inflammatory and neoplastic processes. In particular, the inducible isoenzyme COX-2 is a key
enzyme of the tumorigenesis-inflammation interface. In this context, COX-2 overexpression has been
shown in various tumor entities and is positively correlated with progression, malignancy and poor
patient survival [28]. COX-2 overexpression also contributes to chemo- and radiation resistance [29–35].
Hypoxic and pseudo-hypoxic signaling additionally influences COX-2-mediated pathways [26,27,36].
Therefore, studies have been initiated on the use of selective COX-2 inhibitors (coxibs) as targeted
chemotherapeutic agents and potential radiosensitizers [28,37].
Endoradiotherapy, e.g., with [177Lu]Lu-DOTA-(Tyr3)octreotate (177Lu-DOTA-TATE) is currently
investigated as a treatment option for inoperable or metastatic PPGLs, showing promising effects,
but sometimes incomplete tumor remission in clinics as well as in preclinical PPGL models [38–40].
COX-2 is associated with chemo- and radiation resistance and poor patient outcome in a number of
tumor entities [29–35] encouraging us to investigate whether COX-2 is a potential target in PPGLs.
The first report on COX-2 gene expression and immunohistochemistry in adrenal pheochromocytomas
was published in 2001 suggesting that the enzyme might have a role in malignant transformation of these
tumors [41]. Between 2007 and 2011, another four immunohistochemical studies were published supporting
the value of COX-2 as surrogate marker that, in association with other factors, could potentially discriminate
between benign and metastatic pheochromocytoma [42–45]. Due to literature showing that COX-2 is
induced by hypoxia signaling [46,47], we hypothesized that cluster I PPGLs have a higher COX-2 expression
than cluster II. Accordingly, COX-2 may be a promising molecular target for functional imaging and adjuvant
treatment, in particular in cluster I PPGLs.
To address the above hypothesis, we evaluated COX-2 status of PPGLs with known mutational
status for VHL, SDHx, EPAS1, NF1, RET, and HRAS on both mRNA and protein level. Furthermore,
we characterized COX-2 immunoreactivity in tumor spheroids and allografts derived from mouse
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pheochromocytoma (MPC) cells with a heterozygous Nf1 knockout [48,49] in order to assess the
usefulness of these models for preclinical testing of COX-2-targeting adjuvant and, in particular,
radiosensitizing treatments.
2. Results
2.1. COX-2 Gene Expression in Clinical PPGL Samples
COX-2 gene expression data were extracted from gene expression arrays [50,51] of 70 PPGL
samples with documented mutations in tumor susceptibility genes (Table 1). This series reflects
the expected age, location, and metastatic disease, according to the mutations involved. Most cases
were adrenal pheochromocytomas (67%), followed by thoracic and abdominal paragangliomas (29%),
and head and neck paragangliomas (7.1%). Germline mutations were documented in 60% of cases.
At the time of investigation 8.6% of cases showed metastatic disease. Most of the tumors carried
mutations in SDHx (23% comprising 5 SDHD, 2 SDHC, and 9 SDHB, cases) and RET (23%) followed
by VHL (21%), EPAS1 (16%), HRAS (11%), and NF1 (5.7%). The SDHx subgroup showed the highest
proportion of extra-adrenal paragangliomas (62% thoracic and abdominal, and 31% head and neck),
followed by EPAS1 (73% thoracic and abdominal). All other genetic subgroups included mostly
adrenal pheochromocytomas (85−100%). All subgroups showed similar means in tumor diameters
(4.4−5.9 cm). Metastatic disease was most frequently documented among SDHx-mutant cases (25%)
compared to all other genetic subgroups (0−18%).
Table 1. Tumor characteristics and clinical features of 70 PPGL patients extracted from [50,51] for
COX-2 gene expression analysis; (A) adrenal; (TA) thoracic and abdominal; (HN) head and neck.
Mutant Gene VHL SDHx 1 EPAS1 NF1 RET HRAS Total
Total cases (n) 15 16 11 4 16 8 70
Hereditary (n) 10 15 0 3 14 0 42
Sex (n)
Female 6 9 10 4 8 3 40
Male 9 7 1 0 8 2 27
Unknown 0 0 0 0 0 3 3
Tumor location (n)
A 13 1 5 4 16 8 47
A + TA 2 2 2 0 0 0 6
TA 0 8 4 0 0 0 14
HN 0 5 0 0 0 0 5
Tumor diameter (n)
<4 cm 1 6 3 0 4 0 14
≥ 4 and ≤ 8 cm 4 3 5 0 1 4 17
>8 cm 0 1 2 0 1 1 5
Unknown 10 6 1 4 10 3 34
Mean (cm) 4.4 ± 1.0 4.6±1.2 5.8 ± 1.2 n.a. 4.6 ± 1.2 5.9 ± 0.9 5.1 ± 0.5
Age at diagnosis (years)
Range 9−47 10−95 18−78 38−58 18−62 45−79 9−97
Unknown 1 0 0 1 0 2 4
Mean 24 ± 3.1 † 27 ± 7.9 42 ± 6.4 48 ± 5.8 38 ± 6.5 64 ± 4.6 ‡ 36 ± 2.3
Metastatic (n) 0 4 2 0 0 0 6
1 comprising 5 SDHD, 2 SDHC, and 9 SDHB cases; significance of differences tested with Mann–Whitney U test:
† p < 0.01, ‡ p < 0.001; (n.a.) not available.
Statistical analysis taking into account the general clinico-morphologic features of the tumors
showed that gender, tumor location, tumor diameter, age at diagnosis, or metastatic behavior had no
relevant influences on COX-2 gene expression (Table S1). On the other hand, COX-2 expression was
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significantly higher in head and neck PPGLs (p = 0.01) compared to other locations. Of note, all head
and neck PPGLs in this series were related to an SDHD germline mutation.
PPGLs carrying a VHL mutation showed the highest COX-2 expression (0.30 ± 0.28), followed
by cases with SDHx (−0.13 ± 0.22), EPAS1 (−0.25 ± 0.13), HRAS (−0.55 ± 0.12), RET (−0.68 ± 0.14),
and NF1 (−0.96 ± 0.16) mutations (Figure 1). The mean COX-2 expression among all cluster I tumors
was higher (−0.01 ± 0.14) compared to cluster II (−0.68 ± 0.09). COX-2 expression was similar in
hereditary (−0.26 ± 0.15) and somatic cases (−0.31 ± 0.11). COX-2 expression showed significant
positive relationships with VHL mutations (r = 0.371, p = 0.002) and cluster I transcriptional signature
(r = 0.406, p < 0.001), respectively.
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Figure 1. Normalized COX-2 gene expression in PPGLs with regard to genetic background. gene
expression array data were derived from Lopez-Jimenez et al. [50] and Qin et al. [51] mRNA expression
series. Seventy samples with known genotype were included in this analysis and classified according
to the specific gene mutated, origin of mutations, and transcriptional cluster; numbers in parentheses
represent the number of samples investigated in each subgroup; see Table S1 for statistical analyses.
To further investigate a possible association between the pseudohypoxic signature and COX-2 in
cluster I PPGLs, unsupervised clust ring for 97 hypoxia-related genes (see materials and methods for
details) showed that VHL- an SDHx-mutant cases clustered together (Figure S1). Pe rson correlation
for COX-2 expression and pseudohypoxic signature indicated significant relationships (p < 0.05)
86 out of 171 probes, representing 65 out of 97 genes related to hypoxia in PPGLs (Table S2).
Correlation c effici nts ra ged from 0.19 to 0.63 with 65 pr bes having only a we k correlation below
0.4. Ex mplary, consistent with high COX-2 ex ession, the analysis showed a significant positive
relationship with mRNA levels of a2+-dependent phospholipase A2 (r = 0.564, p < 0.001) nc
the enzyme is required for releasing rachidonic acid from phospholipid membranes as the sp cific
substrate for cyclooxygenas s.
2.2. COX-2 Immunoreactivity in Clinical PPGL Tissue Samples of a Second Cohort
COX-2 immunoreactivity was assessed in formalin-fixed paraffin-embedded tumor samples from
a separate cohort sharing no case with the RNA sample cohort. This series included 96 PPGLs with
a clinically documented mutation in tumor susceptibility genes (Table 2) and reflects the expected
age, location, and metastatic isease, according to the mutations involved. Most cases were adrenal
pheochromocytomas (52%), followed by thoracic and abdominal paragangliomas (26%), and head and
neck paraganglio as (22%). Germline mutations were documented in 52% of cases. At the time of
investigation, 13% of cases showed metastatic disease.
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Table 2. Tumor characteristics and clinical features of 96 PPGL tissue samples available for COX-2
immunohistochemistry classified with regard to mutations in different tumor susceptibility genes;
(A) adrenal; (TA) thoracic and abdominal; (HN) head and neck.
Mutant Gene VHL SDHx 1 EPAS1 NF1 RET HRAS Total
Total cases (n) 14 39 7 21 9 6 96
Hereditary (n) 7 38 0 0 4 0 50
Sex (n)
Female 6 18 6 9 4 4 47
Male 8 21 1 12 5 2 49
Tumor location (n)
A 10 4 4 20 8 4 50
TA 3 15 3 1 1 2 25
HN 1 20 0 0 0 0 21
Tumor diameter (n)
<4 cm 3 22 2 6 2 2 35
≥4 and ≤8 cm 7 13 5 11 3 3 44
>8 cm 0 2 0 0 3 0 5
Unknown 4 2 0 4 1 0 12
Mean (cm) 4.6 ± 0.6 3.9 ± 0.4 * 4.5 ± 0.6 4.1 ± 0.3 7.2 ± 1.5 * 3.8 ± 0.5 4.4 ± 0.3
Age at diagnosis (years)
Range 9−49 14−71 17−75 20−74 33−72 28−81 9−81
Mean 25 ± 3.9 ‡ 38 ± 2.7 † 42 ± 8.7 52 ± 2.8 † 49 ± 4.2 58 ± 7.2 * 42 ± 1.7
Metastatic (n) 1 8 0 1 1 1 12
1 comprising 18 SDHD, 3 SDHC, 9 SDHB, 5 SDHA, and 4 SDHAF2 cases; significance of differences tested with
Mann–Whitney U test: * p < 0.05, † p < 0.01, ‡ p < 0.001.
Most of the cases carried a mutation in SDHx (41% comprising 18 SDHD, 3 SDHC, 9 SDHB,
5 SDHA, and 4 SDHAF2 cases) followed by NF1 (22%), VHL (15%), RET (9.4%), EPAS1 (7.3%), and HRAS
(6.3%). The SDHx subgroup showed the highest proportion of extra-adrenal paragangliomas (39%
thoracic and abdominal, and 51% head and neck), whereas all other genetic subgroups included mostly
adrenal pheochromocytomas (57−95%). Tumor diameters were significantly smaller in the SDHx
subgroup (3.9 cm) and significantly higher in the RET subgroup (7.2 cm) compared to cases with other
genetic backgrounds. Metastatic disease was most frequently documented among SDHx cases (21%)
compared to all other genetic subgroups (0−17%).
COX-2 immunoreactivity was assessed by three observers using a three-mark score taking
into account the percentage of positively stained tumor cells per tissue section (Figure 2). Sections
with ‘strong’ (>50% of tumor cells stained) or ‘moderate’ score (20–50% of tumor cells stained)
showed cytoplasmic COX-2 immunoreactivity in pheochromocytes and/or interconnected stromal cells.
Tumors with ‘negative or weak’ score (<20% of tumor cells stained) showed COX-2 immunoreactivity
predominantly in few stromal cells scatted over the tissue section. Interobserver variation statistics
showed good agreement between the first two observers (weighted κ = 0.67). However, there were
14 cases of disagreement (15%) between ‘negative or weak’ and ‘moderate’ scores as well as 16 cases of
disagreement (17%) between ‘moderate’ and ‘strong’ scores that where passed to a third observer for
final decision.
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(Table S1). On the other hand, COX-2 immunoreactivity was significantly higher in samples from male
patients compared to females and all genetic subgroups showed different sex ratios. However, multiple
regression analyses, testing the relationships between COX-2 expression and the two independent
variables ‘genetic background’ and ‘sex’ simultaneously, showed that trends in COX-2 immunoreactivity
of the genetic subgroups were not artifacts of different sex ratios.
In tissue samples with different genetic backgrounds, a trend was observed with highest COX-2
immunoreactivity in PPGLs due to VHL mutations (36% strong, 43% moderate), followed by NF1
(33% strong, 43% moderate), SDHx (23% strong, 41% moderate), HRAS (17% strong, 33% moderate),
EPAS1 (14% strong, 29% moderate), and RET (all samples negative or weak) (Figure 3). Of note, COX-2
immunoreactivity showed similar incidences in different SDH subtypes. However, due to higher
numbers of SDHD-mutant cases compared to the other subtypes, multiple regression analyses (Table S2)
taking also into account the sex of the patients showed a significant positive relationship between SDHD
mutation and COX-2 immunoreactivity (r = 0.867, p ≤ 0.001). A negative relationship was detected
between RET mutation and COX-2 immunoreactivity (r = −0.948; p < 0.001). COX-2 immunoreactivity
was similar in hereditary cases (24% strong, 37% moderate) compared to somatic cases (24% strong,
37% moderate). The trend for higher COX-2 immunoreactivity in cluster I (25% strong, 40% moderate)
compared to cluster II (22% strong, 31% moderate) was related to different sex ratios in these groups
(r = 0.323, p = 0.043).
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showed a significant positive relationship between SDHx mutations and COX-2 immunoreactivity
with stromal cells involved (r = 0.266, p = 0.009).Cancers 2019, 11, x 8 of 17 
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2.3. COX-2 as Molecular Target in Preclinical PPGL Models
We further assessed the COX-2 status of a commonly used preclinical model of mouse
pheochromocytoma (MPC) cells with heterozygous Nf1 knockout. In vitro, MPC spheroids showed
strong and homogeneous COX-2 immunoreactivity in pheochromocytes involving the most peripheral
8−10 cellular layers, whereas COX-2 immunoreactivity was absent in the necrotic core (Figure 5A).
In vivo, MPC tumors in a subcutaneous allograft model showed strong tumor-specific uptake of
a red-fluorescent COX-2 imaging probe (Figure 5B). Tissue sections from these allografts showed strong
and homogenous COX-2 immunoreactivity predominantly involving pheochromocytes.
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3. Discussion
Endoradiotherapy, e.g., with 177Lu-DOTA-TATE is currently investigat d as treatment option
for inoperable or metastatic PPGLs, showing promising effects, but sometimes incomplete tumor
remission in clinics as well as in preclinical models [38–40]. COX-2 is associated with chemo- and
radiation resistance and poor patient outcome in a number of tumor entities [29–35] encouraging
us to investigate whether X-2 is a potential target in PPGLs. Inhibition of COX-2 is considered
a viable radiosensitization strategy [24,35]. In particular, selective COX-2 inhibitors (coxibs) have
been suggest d f r combinati n radiotherapy of tumors, thereby enhancing radiosensitivity in
various settings [28,35,37].
Expression of COX-2 was assessed on mRNA or protein level in two separate cohorts of PPGL
patients with known tumor driver mutations. Both cohorts w re comprised of tumors with a similar
distribution of clinical features in respect to sex, tumor location, age at diagnosis, and metastatic
behavior, reflecting previously described features of PPGLs [52].
Despite a sig ificant increase in COX-2 mRNA le ls in cluster I c mpared to cluster II PPGLs,
we did not find a significant relationship between the pseudohypoxic transcriptional signature of
cluster I PPGLs and COX-2 in clinical samples. COX-2 protein levels are consistent with these results
showing also no significant difference between cluster I and cluster II PPGLs. T is may be due to
the fact that PPGLs are characterized by a high degree of intertumoral heterogeneity. Many different
factors have been described to activate and interfere with COX-2 in cancer [28]. Amongst others,
intratumoral differences in normoxic/hypoxic conditions, systemic chemoth r py, oxidative stress,
or even tobacco smoking can interfere with COX-2 levels on gene expression and protein level, possibly
masking a potential association with the pseudohypoxic signature of cluster I PPGLs. Nevertheless,
trends were observed that may at least partially be explained by the underlying genetic background.
In cluster I PPGLs with loss-of-function mutations in VHL and SDHx, pseudohypoxic transcriptional
phenotypes may contribute to COX-2 induction on gene expression and protein level. Functional defects
of VHL, an E3 ubiquitin ligase, directly impair ubiquitin labeling of hypoxia-inducible factors (HIF-α) for
regular proteasomal degradation. Functional defects of SDH indirectly impair ubiquitin-labeling of HIF-α
caused by intracellular accumulation of succinate, an intrinsic inhibitor of prolyl hydroxylases. Therefore,
both VHL and SDH defects are associated with enhanced HIF-α signaling even under normoxic conditions,
a metabolic state referred to as pseudohypoxia [25]. From investigations on other tumor entities, in particular
on colon cancer, it is known that both HIF-α isoforms (1 and 2) are capable of directly upregulating
COX-2 expression [26,27].
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COX-2 mRNA levels as well as the percentage of moderate and high COX-2 immunoreactivity
tended to be lower among cases carrying a gain-of function mutation in EPAS1, encoding the HIF-2α
protein, compared to VHL- and SDHx-mutant cases. This observation suggests that activation of
HIF-2α alone may not be sufficient for COX-2 upregulation in PPGLs.
In cluster II PPGLs with loss-of-function mutations in NF1 gene, the trend for a relatively high
COX-2 immunoreactivity is consistent with another report on elevated COX-2 and prostaglandin E2
(PGE2) levels in NF1 malignant peripheral nerve sheath tumors [53]. These observations raise the
possibility that functional defects in NF1, a GTPase-activating protein, could indirectly contribute to
the upregulation of COX-2 expression. This may at least be partly explained by elevated levels of
activated Ras-GTP leading to hyperactivation of mitogen-activated protein kinase (MAPK) pathways.
Under normoxic conditions, COX-2 expression can be induced through activation of oncogenic
pathways such as Ras-MAPK and can even be further enhanced by HIF-1α during hypoxia [36].
The lack of high COX-2 mRNA in the gene expression cohort might be due to the low number of
NF1-mutant cases in this particular set of tumors. On the other hand, all NF1 cases in the RNA sample
cohort carried germline mutations, whereas all NF1 cases in the tissue sample cohort carried somatic
mutations. Whether there is a relationship between germ line or somatic NF1 mutations and different
COX-2 levels in PPGLs remains to be investigated.
In accordance with the observations in clinical PPGL samples, COX-2 immunoreactivity was
also high in spheroids and subcutaneous allografts derived from mouse pheochromocytoma (MPC)
cells with a heterozygous Nf1 knockout. Therefore, these models are suitable for preclinical testing
of COX-2-targeted treatments for the management of PPGLs. Since we did not find a significant
relationship between tumor driver mutations and COX-2 in clinical PPGL samples, molecular imaging
could be applied in a personalized approach to pre-estimate whether a tumor is susceptible to
COX-2-targeted treatment. In our study, specific accumulation of a red-fluorescent COX-2 probe in
subcutaneous MPC allografts demonstrates the potential value of COX-2 tracers for assessing the target
status in PPGLs non-invasively. In order to translate this approach into clinical practice, studies have
been initiated on the use of selective COX-2 inhibitors as PET radiotracers for cancer imaging [54–56].
In the case of HRAS and RET mutations, trends for lower COX-2 mRNA levels in PPGLs are in
agreement with COX-2 immunoreactivity. These findings suggest that both HRAS and RET have not
major role in regulating COX-2 expression in PPGLs. However, there have been reports on fibroblasts
transformed with a mutant HRAS responding with a rapid induction of COX-2 on gene expression
and protein level [57]. It has also been reported that HRAS expression increases COX-2 expression in
intestinal epithelial cells [58]. In thyroid cancer, RET has been shown to activate Ras, and thus it could
indirectly lead to COX-2 activation, however, whether RET could activate COX-2 in any other way is
a matter of investigation [59].
The observation that tumor diameter and age at diagnosis had no statistically relevant impact
on COX-2 levels is in accordance with previous studies [41–45]. In contrast to these reports, we did
not detect a statistically relevant increase of COX-2 mRNA and COX-2 immunoreactivity in primary
tumors of metastatic PPGLs. This is most likely due to the relatively small number of metastatic
cases in our cohorts. Significantly higher COX-2 mRNA levels in head and neck PPGLs compared
to other tumor locations is related to the fact that all head and neck PPGLs in this series carried an
SDHD mutation. This raises the possibility that COX-2 expression may be regulated by SDHD-related
metabolic alterations in particular in head & neck PPGLs. However, due to low sample numbers
available in the SDHD subgroup, further studies focusing on COX-2 expression in specific SDH
mutation subtypes are necessary to draw a conclusion from these initial observations. In our tissue
series, head and neck PPGLs comprised of cases with different tumor driver mutations explaining why
similar effects on COX-2 were not detected in this series. Significantly higher COX-2 protein in PPGLs
from male patients compared to females is considered a specific characteristic of our tissue sample
cohort since we did not detect a similar effect in the RNA samples.
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Higher COX-2 immunoreactivity in stromal cells of PPGLs related to SDHx germline mutations
compared to other tumor driver mutations indicates a systemic effect of partial SDHx loss on COX-2
levels. This pattern of COX-2 immunoreactivity may be related to structure-supporting sustentacular
cells and/or a characteristic monocytic component in PPGLs that has recently been discovered [60].
Further histologic investigations are required to elucidate the specific cell populations of stromal COX-2
immunoreactivity in PPGLs. A report on COX-2 in cervical cancer showed that the ratio between
COX-2 in tumor cells and COX-2 in stroma cells was very effective in distinguishing patients with
low versus high risk of death from disease. A very strong relationship between both tumor COX-2
expression and tumor-to-stromal COX-2 ratio has been shown to be highly correlated with response to
chemotherapy while, high COX-2 expression in the stroma was significantly associated with better
survival, but failed to directly correlate with response to treatment [61]. Further studies are required to
fully elucidate the role of COX-2 in PPGL tumorigenesis and therapy resistance.
4. Materials and Methods
4.1. Tumor Samples and Genetic Testing
For immunohistochemical analysis, a series of 96 tumors from patients with confirmed PPGL
diagnosis were used for this study. The cohort was recruited in the four participating centers: Tumor
and Normal Tissue Bank of the UCC/NCT at the Universal Hospital Carl Gustav Carus, Dresden,
Germany, Spanish National Cancer Research Centre, Madrid, Spain, Radboud University Medical
Centre, Nijmegen, The Netherlands, and University of Florence, Italy. All patients provided informed
consent to collect clinical and genetic data, in accordance with institutional ethical-approved protocols
for each center. Metastatic cases were defined based on clinical documentation of metastases or
extensive local invasion. Genetic screening was performed in germline and tumor DNA using
a next-generation sequencing panel (PheoSeq) as previously described [62].
4.2. Gene Expression Profiling and Data Processing
Gene expression array data were extracted from [50,51]. To investigate the association between
a pseudohypoxic transcriptional signature and COX-2 in cluster I PPGLs on RNA level, a published
list of 782 genes significantly differentially expressed between VHL- and SDHB-mutant cases was
taken into account [50]. These genes were compared with the hypoxia database including all genes
theoretically related to hypoxia [63]. Unsupervised clustering was applied with 97 hypoxia-related
genes overlapping from both lists (Figure S1). Pearson correlation coefficients® were calculated
between COX-2 expression and each of the 97 genes.
4.3. COX-2 Immunohistochemistry
Formalin-fixed and paraffin-embedded tumor and spheroid sections (3 µm) were dewaxed using
Roticlear (Carl Roth, Karlsruhe, Germany) and rehydrated in a graded series of ethanol. Antigen
retrieval was performed in 10 mmol/L citrate buffer pH 6 intermittently heated to 100 ◦C in 5 min
intervals. Washing was performed using 0.05 mol/L Tris-buffered saline pH 8 containing 0.5% (v/v)
Tween-20 (TBS-T). Endogenous peroxidase was quenched using 3% H2O2 in TBS-T. Endogenous
avidin and biotin were blocked using a commercially available avidin/biotin quenching system
(Agilent, Santa Clara, CA, USA). Non-specific binding sites were blocked using 10% fetal bovine serum
(v/v) in TBS-T. COX-2 was detected using the primary antibody ab15191 (Abcam, Cambridge, UK).
Isotype controls were incubated with non-specific rabbit IgG ab27478 (Abcam). Specific binding
was detected using the biotinylated secondary antibody 111-065-003 (Dianova, Hamburg, Germany)
and ExtrAvidin-peroxidase E2886 (Sigma-Aldrich, St. Louis, MO, USA) followed by staining with
3-amino-9-ethylcarbazole substrate (Sigma-Aldrich). Tumor sections were counterstained with Meyer’s
hematoxylin, mounted with Kaiser’s glycerol gelatin (Carl Roth), and imaged using the AXIO Imager
A1 microscope (Carl Zeiss, Oberkochen, Germany).
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4.4. Scoring of COX-2 Immunoreactivity
For each case, COX-2 immunoreactivity was analyzed from a series of bright field images
(magnification, ×100) contiguously captured along the diameter of one tumor section (images
per section > 5). Perinuclear and cytoplasmic red-brown staining was considered positive. PPGLs form
dense, reticular to glandular ‘zellballen’ or intermediate forms [64]. Typically, structure-supporting
sustentacular cells are closely associated with tumor cells [65]. Taking into account these specific
histologic features of PPGLs, our examination assessed COX-2 immunoreactivity in both inflammatory
and sustentacular cells of the stromal compartment and/or pheochromocytes.
The percentage of COX-2-positive tumor cells was assessed using a three-mark score adapted from [41]:
negative or weak (<20% of tumor cells); moderate (20–50% of tumor cells); strong (>50% of tumor cells).
Samples were evaluated independently by two histologically experienced observers (Martin Ullrich and
Verena Seifert) who were blinded to the genetic subtype of tumors. In cases of disagreement, samples were
referred to a third observer for final decision (Sandra Hauser). Notably, our scoring system does not report
on staining intensities that were observed to vary between samples from different centers most likely due to
differences in tissue quality, preservation techniques, and storage time.
4.5. Spheroid Models
Mouse pheochromocytoma cells (MPC clone 4/30PRR [48]) were cultivated as previously described [49].
Spheroids were generated from MPC cells passage 34 as described elsewhere [66,67]. After 18 days of
cultivation, spheroids (diameters between 500 and 600 µm) were fixed in paraformaldehyde and embedded
in paraffin according to standard procedures (n = 6).
4.6. Tumor Allograft Models
Animal experiments were carried out at the Helmholtz-Zentrum Dresden-Rossendorf according to
the guidelines of German Regulations for Animal Welfare and have been approved by the local Animal
Ethics Committee for Animal Experiments (Landesdirektion Dresden, Germany). Subcutaneous
tumor allografts were generated through injection of luciferase-expressing MPCLUC/eGFP-ZEO cells
(abbreviated as MPCLUC/GZ) passage 11 into female NMRI-nude mice (Rj:NMRI-Foxn1nu, homozygous,
T cell-deficient, hairless; Janvier Labs, Le Genest-Saint-Isle, France) as described previously. Five weeks
after cell injection, optical in vivo imaging was performed (tumor diameters between 0.8 and 1.2 mm).
After imaging, mice were sacrificed using CO2 inhalation and cervical dislocation. Tumors were excised,
fixed in paraformaldehyde, and embedded in paraffin according to standard procedures (n = 6).
4.7. Optical In Vivo Imaging
Optical tumor imaging in mice was performed on a preclinical In-Vivo Xtreme imaging system
(Bruker, Billerica, MA, USA) under general anesthesia with inhalation of 10% (v/v) desflurane (Baxter,
Unterschleißheim, Germany) in 30% (v/v) oxygen air. Location and morphology of luciferase-expressing
MPCLUC/GZ allografts were assessed using bioluminescence imaging (BLI) as described previously [49].
Functional COX-2 imaging was performed using the RediJect COX-2 Fluorescent Imaging Probe
(PerkinElmer, Waltham, MA, USA) injected intraperitoneally according to manufacturer’s instructions.
Fluorescence imaging (FLI) was performed three hours after injection. Specific fluorescence of the
imaging probe was captured at λEx/Em = 570/600 nm and non-specific fluorescence was captured
at λEx/Em = 480/535 nm. Tumor uptake was analyzed in processed images, showing specific
fluorescence/non-specific fluorescence ratios.
4.8. Statistical Analysis
Graphs were drawn using Prism version 5.02 (GraphPad Software, San Diego, CA, USA). Incidences
of COX-2 immunoreactivity within a defined subgroup are presented as percent of cases, n represents
the number of cases. If not stated differently, data are presented as means ± standard error of the
Cancers 2019, 11, 743 13 of 17
means. Significance of differences was tested for n ≥ 6 using the Mann–Whitney U test. Multiple linear
regression analysis was performed using OriginPro 2017G (OriginLab Corporation, Northhampton,
MA, USA). Relationships were described with the regression coefficient r and considered significant at
p-values < 0.05. Interobserver variation was calculated using online QuickCalcs κ statistics version
06/2014 (GraphPad Software, www.graphpad.com/quickcalcs/kappa1).
5. Conclusions
Moderate to high cyclooxygenase 2 (COX-2) gene expression and immunoreactivity in about
60% of PPGLs demonstrates that, for these patients, COX-2 is considered a clinically relevant
molecular target for adjuvant, in particular radiosensitizing treatments using selective COX-2 inhibitors,
e.g., in combination with 177Lu-DOTA-TATE endoradiotherapy. However, taking into account the
genetic background of the samples, is an indicator but not the major determinant for COX-2 expression
in PPGLs. High COX-2 immunoreactivity in tumor spheroids and subcutaneous tumor allografts
derived from mouse pheochromocytoma (MPC) cells demonstrates that available PPGL models are
suitable for preclinical in vitro and in vivo testing of COX-2-targeting treatments.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/6/743/s1,
Figure S1: Unsupervised clustering for 97 hypoxia-related genes in PPGLs applied to our mRNA expression
series extracted from [50,51]; VHL- and SDHx-mutant cases clustered together whereas, other cases showed no
homogeneous profile, Table S1: Statistical analyses of COX-2 status with regard to clinical characteristics and
genetic background of tumors in two independent series of PPGL samples; data in parentheses were calculated
from low sample numbers (n < 7); as Mann–Whitney U test showed significant sex-related differences in COX-2
immunoreactivity in tissue samples, multiple regression analyses was applied to distinguish whether the trends
observed in the genetic subgroups were related to genetic background or different sex ratios only; levels of
significance: * p < 0.05; † p <0.01, ‡ p < 0.001, Table S2: Pearson correlation between expression of COX-2 and
97 hypoxia-related genes in PPGLs in the mRNA expression series extracted from [50,51].
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